Unitaid audited financial report for the year ended 31 December 2021
Unitaid Strategy 2023-2027
Financial Guidelines for Unitaid Grant Implementers (Frequently Asked Questions)
Unitaid 2017-2021 Strategy Review, Management Response, Dec 2021
Unitaid 2017-2021 Strategy Review, Final Report, Vol 2, Annexes
Unitaid 2017-202 Strategy Review, Final Report, Vol 1, Main report
Multipurpose prevention technologies: Technology landscape and potential for low- and middle-income countries
Financial guidelines for Unitaid grant implementers
Unitaid’s climate and health strategy 2023-2027
Unitaid’s investment case 2023-2027, executive summary
Unitaid’s investment case 2023-2027
Unitaid Strategy 2023-2027
Maternal and newborn health
Women’s and children’s health
Biomarkers for acute febrile illness at the point-of-care in low-resource settings. Meeting report
Accelerating access to innovative point-of-care HIV diagnostics: Lessons learned from UNICEF
Innovative delivery systems for paediatric medicines technology landscape
Disease Narrative for hepatitis C
Disease narrative for tuberculosis
Disease Narrative for malaria
Disease Narrative for HIV
Hepatitis C diagnostics technology landscape – May 2019
Unitaid and the Government of Spain
About Unitaid (Saving lives faster)
Unitaid and the UK Government
Unitaid audited financial report for the year ended 31 December 2023
Partnership report: Unitaid and the Global Fund to Fight AIDS, Tuberculosis and Malaria
Unitaid audited financial report for the year ended 31 December 2022
Impact story: Improving use of tuberculosis diagnostics
Impact story: Improving severe malaria outcomes
Impact story: Accelerating access to seasonal malaria chemoprevention
Impact story: HIV Self-Testing
Impact story: Improved treatment for HIV: Dolutegravir
Impact story: Early-infant diagnosis of HIV using point-of-care technologies
Impact story: Medicines Patent Pool
Impact story: Childhood tuberculosis
